Heidelberg Pharma Ag · XETR:HPHA
Heidelberg Pharma — FY2024 Earnings Presentation
24 slides from Heidelberg Pharma's earnings presentation, Mar 24, 2025
Slide 1: The Leader in Next Generation ADC Payloads
THE LEADER IN NEXT GENERATION ADC PAYLOADS FY 2024 Financial Results & Business Update • 24 March 2025
Slide 2: Safe Harbor: Forward Looking Statements
SAFE HARBOR FORWARD LOOKING STATEMENTS This communication contains certain forward-looking statements, competition from other biopharmaceutical, chemical and relating to the Company’s business, which can be identified by the pharmaceutical companies, environmental, health and safety matters, use of
Slide 3: Corporate Highlights
CORPORATE HIGHLIGHTS PROPRIETARY PAYLOADS, WHOLLY-OWNED ASSETS & CLINICAL CANDIDATES Our Company Complete GMP Manufacturing Supply Chain • Heidelberg Pharma Group: 116 employees • Listed on Frankfurt Stock Exchange: HPHA Technology and Asset Partnerships Maximize Value of Pipeline Lead ADC Program H
Slide 4: Next Generation ADC Payload Platform
NEXT GENERATION ADC PAYLOAD PLATFORM Developing an ADC toolbox and clinical product pipeline to overcome tumor resistance across cancer types Toolbox of proprietary payloads ATAC technology RNA polymerase II inhibitor Amanitin-based ETAC ITAC technology technology Topoisomerase I TLR7 agonist inhibi
Slide 5: Growing Pipeline of Proprietary Programs
GROWING PIPELINE OF PROPRIETARY PROGRAMS Product Target Indication Research Preclinic Phase I Phase II Phase III Approval Partner Huadong HDP-101 BCMA Multiple Myeloma ------------------------------------------------------------------------------------------ (China+) ATAC pipeline HDP-102 CD37 NHL (
Slide 6: Growing Pipeline of Partnered Programs
GROWING PIPELINE OF PARTNERED PROGRAMS Product Target Indication Research Preclinic Phase I Phase II Phase III Approval Partner Partners ATAC TAK-ATAC n/a Oncology ------------------------------------------------------------------------------------------ Takeda Product Target Indication Research Pre
Slide 7: R&D Update – Focus on ATAC Platform
R&D UPDATE – FOCUS ON ATAC PLATFORM © Heidelberg Pharma AG 7
Slide 8: Lead Program: HDP-101 in Multiple Myeloma
LEAD PROGRAM: HDP-101 IN MULTIPLE MYELOMA Multiple Myeloma (MM) is a type of blood cancer PHASE I/IIa CLINICAL TRIAL • … that develops from plasma cells in the bone marrow and can affect more than one part of the body Phase I part: dose escalation (ongoing) • Cohorts of 2-6 patients are treated • In
Slide 9: HDP-101 – Phase I Preliminary Efficacy Data
HDP-101 – PHASE I PRELIMINARY EFFICACY DATA * Complete Response * * Readout: November 2024 Treatment duration (days) Progressive disease (PD) Partial response (PR) Very good partial remission (VGPR) End of treatment Minimal response (MR) Stable disease (SD) Complete response (CR) * Adverse Event, mo
Slide 10: Dose Optimization Strategies from Cohort 6
DOSE OPTIMIZATION STRATEGIES FROM COHORT 6 After Cohort 5, a detailed safety analysis was performed in January C8 RP2D 2025 Q1W split C7 For cohort 6, the Safety Review Committee (SRC) recommended dosing • to continue the clinical study and Split 1st dose & C7 premed*, then Q3W • mitigate the transi
Slide 11: Cohort 6 Summary and Cohort 7 Outlook
COHORT 6 SUMMARY AND COHORT 7 OUTLOOK Cohort 6 has been completed • 10 patients treated (3-4 patients per arm) • No Dose Limiting Toxicities observed So far, 34 heavily treated patients • The Safety Review Committee unanimously confirmed that 90µg/kg is safe and recommended to escalate the dose rece
Slide 12: Next ATAC Candidate: HDP-102 in Non-Hodgkin Lymphoma
NEXT ATAC CANDIDATE: HDP-102 IN NON-HODGKIN LYMPHOMA Non-Hodgkin lymphoma (NHL) is one of the more common types of cancer • HDP-102 targets the Antigen CD37 that is overexpressed on B-cell lymphoma cells • Preclinical trials show broad therapeutic window • Clinical Trial Application (CTA) data packa
Slide 13: First-in-Human Clinical Trial with HDP-102 in NHL
FIRST-IN-HUMAN CLINICAL TRIAL WITH HDP-102 IN NON-HODGKIN LYMPHOMA Multicenter, multinational open-label Phase Ia/Ib PHASE Ia PHASE Ib • Dose escalation study • Dose expansion study • Up to 42 patients with relapsed / refractory B-cell Malignancies • 15 patients • Evaluate the safety, tolerability,
Slide 14: Next ATAC Candidate: HDP-103 in Prostate Cancer
NEXT ATAC CANDIDATE: HDP-103 IN PROSTATE CANCER Prostate cancer is the second most common cancer in men • PSMA is overexpressed in nearly all cases of prostate cancer; limited expression in normal tissue • Target indication is metastatic Castration-Resistant Prostate Cancer (mCRPC) • Prevalence of 1
Slide 15: Legacy Portfolio: Partner Telix Brings TLX250-CDx to Patients
LEGACY PORTFOLIO: PARTNER TELIX BRINGS TLX250-CDx TO THE PATIENTS Imaging of kidney cancer to better Status distinguish benign or malignant lesions • Expanded Access Program in 30 centres in Europe and US • BLA submission accepted by the FDA, PDUFA date: 27 August 2025 (marketing approval) • Telix p
Slide 16: Financials
FINANCIALS © Heidelberg Pharma AG 16
Slide 17: Amendment with HealthCare Royalty (March 2025)
AMENDMENT WITH HEALTHCARE ROYALTY (MARCH 2025) Partial monetization of royalty stream for TLX250-CDx in the field of diagnostic use Up to USD 115m Key terms of the amended agreement between Heidelberg Pharma and HealthCare Royalty: • $25 m upfront payment at closing, no repayment obligation in case
Slide 18: Balance Sheet as of 30 November 2024
BALANCE SHEET AS OF 30 NOVEMBER 2024 Financing activities in 2024 • Cash inflow of € 22.8 million due to the transaction with HealthCare Royalty (HCRx) • Repayment of the final tranche in the amount of € 5 million of the shareholder loan to dievini Assets (€ m) 30.11.2024 30.11.2023 Equity and liabi
Slide 19: Profit and Loss 2024
PROFIT AND LOSS 2024 Guidance 2024 Operating expenses In € m FY 2024 FY 2023 Rev. 10/2024 7% 5% Sales revenue and other income 10.0 – 12.0 12.0 16.8 21% Operating expenses (30.0) – (33.0) (32.6) (38.0) Cost of sales (1.8) (3.3) R&D costs (21.8) (28.1) Administrative costs (6.7) (5.2) 67% Other expen
Slide 20: Financing and Cash Flow as of 30 November 2024
FINANCING AND CASH FLOW AS OF 30 NOVEMBER 2024 Cash Flow (€ m) FY 2024 FY 2023 Operating activities (29.6) (33.7) Shareholdings Investing activities (0.4) 5.9 Freefloat 19% thereof selling Emergence - 6.8 thereof ongoing investing activities (0.5) (0.9) dievini and Financing activities 16.1 (10.0) a
Slide 21: Outlook
OUTLOOK © Heidelberg Pharma AG 21
Slide 22: Guidance 2025
GUIDANCE 2025 In € m FY 2024 Guidance 2025 Sales revenue and other income 12.0 9.0 – 11.0 Operating expenses (32.6) (40.0) – (45.0) Operating result (20.7) (30.0) – (35.0) Cash funds (14.0) 50.0 – 55.0 Cash funds per month (1.2) 4.2 – 4.6 Expected payments of $ 90m from HCRx extend the cash reach in
Slide 23: Leading ADC Pipeline in Liquid & Solid Tumor Indications
LEADING ADC PIPELINE IN LIQUID & SOLID TUMOR INDICATIONS HDP-101 HDP-102 HDP-103 HDP-104 BCMA-ATAC CD37-ATAC PSMA-ATAC GCC-ATAC for r/r Multiple Myeloma for Non-Hodgkin Lymphoma for mCR Prostate Cancer for colorectal cancer • Phase I/IIa Study dose • CTA approval Q4 2024 • First-in-Human enabling •
Slide 24: Thank You for Your Attention!
THANK YOU FOR YOUR Heidelberg Pharma AG Ladenburg, Germany Tel.: +49 6203 10090 ATTENTION! investors@hdpharma.com investors@hdpharma.com www.heidelberg-pharma.com www.heidelberg-pharma.com